Patents by Inventor Elisabeth OLSSON

Elisabeth OLSSON has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
    Patent number: 11660303
    Abstract: A compound of formula (I?) or (I?) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.
    Type: Grant
    Filed: April 30, 2021
    Date of Patent: May 30, 2023
    Assignee: KANCERA AB
    Inventors: Håkan Mellstedt, Styrbjörn Byström, Jan Vågberg, Elisabeth Olsson
  • Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of CX3CR1 and/or CX3CL1
    Patent number: 11339183
    Abstract: There is provided a compound of formula I, wherein R1, R2, Q1 and are as defined herein, which compounds are useful in the treatment of diseases and disorders associated with elevated levels of CX3CR1 and/or CX3CL1, in particular acute and/or chronic inflammation, eye diseases, lung diseases, skin diseases, joint and/or bone diseases, autoimmune diseases, cardiovascular diseases, metabolic diseases, brain diseases, neurodegenerative diseases, pain, cancer, liver diseases, kidney diseases, gastrointestinal diseases, human immunodeficiency virus and mood disorders.
    Type: Grant
    Filed: July 9, 2021
    Date of Patent: May 24, 2022
    Assignee: KANCERA AB
    Inventors: Jan Vågberg, Styrbjörn Byström, Elisabeth Olsson, Mattias Jönsson
  • PHOSPHATE AND PHOSPHONATE DERIVATIVES OF 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES AND THEIR USE IN TREATING CONDITIONS ASSOCIATED WITH ELEVATED LEVELS OF CX3CR1 AND/OR CX3CL1
    Publication number: 20210340167
    Abstract: There is provided a compound of formula I, wherein R1, R2, Q1 and are as defined herein, which compounds are useful in the treatment of diseases and disorders associated with elevated levels of CX3CR1 and/or CX3CL1, in particular acute and/or chronic inflammation, eye diseases, lung diseases, skin diseases, joint and/or bone diseases, autoimmune diseases, cardiovascular diseases, metabolic diseases, brain diseases, neurodegenerative diseases, pain, cancer, liver diseases, kidney diseases, gastrointestinal diseases, human immunodeficiency virus and mood disorders.
    Type: Application
    Filed: July 9, 2021
    Publication date: November 4, 2021
    Inventors: Jan VÅGBERG, Styrbjörn BYSTRÖM, Elisabeth OLSSON, Mattias JÖNSSON
  • PHOSPHATE AND PHOSPHONATE DERIVATIVES OF 7-AMINO-5-THIO-THIAZOLO[4,5-D]PYRIMIDINES AND THEIR USE IN TREATING CONDITIONS ASSOCIATED WITH ELEVATED LEVELS OF CX3CR1 AND/OR CX3CL1
    Publication number: 20210292349
    Abstract: There is provided a compound of formula (I), wherein R1, R2, Q1 and formula (X) are as defined herein, which compounds are useful in the treatment of diseases and disorders associated with elevated levels of CX3CR1 and/or CX3CL1, in particular acute and/or chronic inflammation, eye diseases, lung diseases, skin diseases, joint and/or bone diseases, autoimmune diseases, cardiovascular diseases, metabolic diseases, brain diseases, neurodegenerative diseases, pain, cancer, liver diseases, kidney diseases, gastrointestinal diseases, human immunodeficiency virus and mood disorders.
    Type: Application
    Filed: July 5, 2019
    Publication date: September 23, 2021
    Inventors: Jan VÅGBERG, Styrbjörn BYSTRÖM, Elisabeth OLSSON, Mattias JÖNSSON
  • 2-PHENYLIMIDAZO[4,5-B]PYRIDIN-7-AMINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY
    Publication number: 20210267994
    Abstract: A compound of formula (I?) or (I?) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.
    Type: Application
    Filed: April 30, 2021
    Publication date: September 2, 2021
    Inventors: Håkan MELLSTEDT, Styrbjörn BYSTRÖM, Jan VÅGBERG, Elisabeth OLSSON
  • 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
    Patent number: 11008318
    Abstract: Compound of formula (I?) or (I?) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: May 18, 2021
    Assignee: KANCERA AB
    Inventors: Håkan Mellstedt, Styrbjörn Byström, Jan Vågberg, Elisabeth Olsson
  • 2-phenyl-3H-imidazo[4,5-B]pyridine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
    Patent number: 10550113
    Abstract: A compound of formula (I?) or (I?) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: February 4, 2020
    Assignee: KANCERA AB
    Inventors: Hakan Mellstedt, Styrbjorn Bystrom, Jan Vagberg, Elisabeth Olsson
  • 2-PHENYLIMIDAZO[4,5-B]PYRIDIN-7-AMINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY
    Publication number: 20200024272
    Abstract: Compound of formula (I?) or (I?) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.
    Type: Application
    Filed: July 10, 2017
    Publication date: January 23, 2020
    Inventors: Håkan MELLSTEDT, Styrbjörn BYSTRÖM, Jan VÅGBERG, Elisabeth OLSSON
  • Benzimidazole derivates useful as inhibitors of mammalian histone deacetylase activity
    Patent number: 10512634
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the compound. The compound is useful in therapy, for the treatment of disorders mediated by HDAC6, such as autoimmune disorders, neurodegenerative disorders and hyperproliferative disorders, such as cancer.
    Type: Grant
    Filed: May 11, 2015
    Date of Patent: December 24, 2019
    Assignee: KANCERA AB
    Inventors: Johan Schultz, Jan Vågberg, Elisabeth Olsson, Katarina Färnegårdh, Mattias Jönsson, Kristin Hammer, Lars Krüger
  • BENZIMIDAZOLE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN HISTONE DEACETYLASE ACTIVITY
    Publication number: 20180110755
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the compound. The compound is useful in therapy, for the treatment of disorders mediated by HDAC6, such as autoimmune disorders, neurodegenerative disorders and hyperproliferative disorders, such as cancer.
    Type: Application
    Filed: May 11, 2015
    Publication date: April 26, 2018
    Inventors: Johan SCHULTZ, Jan VÅGBERG, Elisabeth OLSSON, Katarina FÄRNEGÅRDH, Mattias JÖNSSON, Kristin HAMMER, Lars KRÜGER
  • 2-PHENYL-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY
    Publication number: 20180002329
    Abstract: A compound of formula (I?) or (I?) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.
    Type: Application
    Filed: February 1, 2016
    Publication date: January 4, 2018
    Inventors: Hakan MELLSTEDT, Styrbjorn BYSTROM, Jan VAGBERG, Elisabeth OLSSON